July 2 (Reuters) - Viatris ( VTRS ) said on Tuesday that

its unit Mylan is no longer a subject of the U.S. Department of

Justice's antitrust investigation into alleged price fixing in

the generic drug industry.

Viatris ( VTRS ) was formed through the merger of Mylan and Pfizer's

Upjohn in 2020.

Mylan and several major drugmakers such as Israel's Teva

Pharmaceutical Industries and India's Sun

Pharmaceutical Industries have been under the DOJ's

investigation for more than eight years over alleged

anti-competitive business practices in fixing prices of certain

generic drugs.

Multiple states have also filed lawsuits against those

companies for alleged antitrust behavior.

The DOJ has informed Viatris ( VTRS ) that it does not expect to take

any further actions related to the pricing and sales of its

generic drugs.

Viatris ( VTRS ) said it would continue to defend itself against the

remaining civil lawsuits pertaining to these matters.

Shares of Pennsylvania-based Viatris ( VTRS ) were up 1.5% in

premarket trading.